Biostax Corp. engages in the development and marketing of pharmaceutical, biotechnology, and MedTech products. The company is headquartered in Winter Park, Florida. The company went IPO on 2001-07-16. The firm has partnerships in the fields of autoimmunity and immune restoration and are able to deliver solutions today for people that are living with autoimmunity, chronic inflammation, infection, and cancer. Its internal and partner programs comprised of JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that has demonstrated anti-fibrotic, immuno-modulating, and anti-inflammatory activities in preclinical models; Lodonal, is a once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), and LDN, which is a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging.

Industry: Pharmaceutical Preparations Peers: Alzamend Neuro Inc Rezolute Inc Candel Therapeutics Inc Lunai Bioworks Inc Greenwich Lifesciences Inc MediciNova Inc Nuvectis Pharma Inc Shattuck Labs Inc XBiotech Inc